Amoebiasis – a parasitic disease of the human being caused by pathogenic strains of Entamoeba histolitica, is one of the most important health problems of developing countries and one of the most common causes of deaths in parasitic bowel diseases.
According to the WHO classification, asymptomatic and manifest amoebiasis is distinguished, including intestinal (amoebic dysentery and dysentery amoebic colitis) and extra-intestinal (hepatic: acute neural and abscess of the liver, pulmonary and other extraintestinal lesions).
In general, all drugs used to treat amoebiasis can be divided into two groups: “contact” or “luminal” (affecting the intestinal luminal forms) and systemic tissue amoebicides.
Luminal amoebicides are used to treat noninvasive amoebiasis (asymptomatic “carriers”). Enlightened amoebicides are also recommended after the end of treatment with tissue amoebicides for the elimination of amoebas left in the intestine, to prevent relapses.